<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">APOMORPHINE HYDROCHLORIDE</span><br/>(a-po-mor'feen)<br/><span class="topboxtradename">Apokyn, </span><span class="topboxtradename">Apokyn Pen, </span><span class="topboxtradename">Uprima<br/></span><b>Classifications:</b> <span class="classification">central nervous system agent</span>; <span class="classification">dopamine receptor agonist</span>; <span class="classification">antiparkinson agent</span><br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>10 mg/mL injection</p>
<h1><a name="action">Actions</a></h1>
<p>Apomorphine has central dopamine receptor agonist properties. Its mechanism of action in treatment of Parkinson's is unknown,
         but probably is related to stimulation of centrally located postsynaptic dopamine D2-type receptors.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Diminishes hypomobility associated with "off" episodes ("end-of-dose wearing off" and unpredictable "on/off"
         episodes) in persons with advanced Parkinson's disease.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Rescue of "off" episodes associated with advanced Parkinson's disease.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Concomitant use of drugs of the 5-HT<sub>3</sub> antagonist class (e.g., ondansetron, granisetron, dolasetron, palonosetron, and alosetron); hypersensitivity to the drug
         or its ingredients (i.e., sodium metabisulfite); benzyl alcohol hypersensitivity; renal failure; QT prolongation; depression,
         suicidal ideation; decreased alertness, seizures, seizure disorder, unconscious state or coma; pregnancy (category C); lactation.
      </p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Cardiovascular, cerebrovascular, respiratory, renal, or hepatic disease; CNS depression, history of (chronic) depression or
         suicidal ideation; hypotension; vomiting; bradycardia; hypokalemia and hypomagnesemia; older adult; hypersensitivity to sulfite.
      </p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">"Off" Episodes of Parkinson's Disease</span><br/><span class="rdage">
<i>Adult</i>
                  				:</span> <span class="rdroute">SC</span> Start with a test dose where BP can be closely monitored. Escalate test dose no sooner than 2 h after last dose until dose
               is not tolerated or patient has response. If test dose of 0.2 mL (2 mg) is tolerated and has positive response, continue with
               0.2 mL (2 mg); if no response, use test dose of 0.4 mL (4 mg); if tolerated and has a positive response, continue with 0.3
               mL (3 mg); if 0.4 mL test dose is not tolerated, try 0.3 mL (3 mg) test dose; if 0.3 mL is tolerated, continue with 0.2 mL
               (2 mg). May increase by 1 mg every few days, generally should not exceed 0.4 mL (4 mg) as an outpatient. Max dose: 0.6 mL
               as single injection and max 5 injections/d.<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">
<b>Subcutaneous</b>
</span><br/><ul>
<li>The dosing pen is marked in mL, not mg, increments; a 1 mg dose is equal to 0.1 mL.</li>
<li>Aspirate to avoid intravascular injection and ensure the injection is SC and not intradermal.</li>
<li>Rotate SC sites to reduce skin reactions.</li>
<li>If the patient has not received apomorphine in more than 1 wk, reinstitute it by starting with the initial test dose and titrating
            to the desired dose.
         </li>
<li>Apomorphine SC causes nausea and vomiting; thus the recommendation is to give 300 mg of trimethobenzamide PO t.i.d., starting
            3 d before the first injection and continued for at least the first 2 mo of treatment.
         </li>
<li>Store at 15°30° C (59°86° F).</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">Body as a Whole:</span> Weakness, yawning, tiredness. <span class="typehead">CNS:</span> CNS depression, dizziness, drowsiness, headache, lightheadedness, euphoria, restlessness, tremor, depression, <span class="speceff-common">dyskinesias</span>
<i>,</i>
<span class="speceff-common">hallucinations</span>.  <span class="typehead">CV:</span>
<span class="speceff-life">Acute circulatory failure</span>, bradycardia, hypertension, orthostatic hypotension, QT prolongation, vasovagal response, syncope. <span class="typehead"> GI:</span>
<span class="speceff-common">Nausea</span>
<i>,</i>
<span class="speceff-common">vomiting</span>
<i>,</i> hypersalivation, taste perversions. <span class="typehead">Metabolic:</span> Peripheral edema. <span class="typehead">Respiratory:</span> Respiratory depression, tachypnea, cough, pharyngitis, rhinitis. <span class="typehead">Skin:</span> Contact dermatitis, <span class="speceff-common">bruising</span>
<i>,</i> granuloma, pruritus, sweating. <span class="typehead">Urogenital:</span>
<span class="speceff-common">Frequent penile erections</span>, painful erections. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span>
<b>Alosetron, dolasetron, granisetron, ondansetron, palonosetron</b> may cause severe hypotension and unconsciousness; <b>alfuzosin, amoxapine, bepridil, chloroquine, clozapine, cyclobenzaprine, droperidol, flecainide, halofantrine, halothane,
         levomethadyl</b>
<b>,</b>
<span class="classification">local anesthetics, macrolides</span>
<b>(clarithromycin, erythromycin, troleandomycin), maprotiline, mefloquine, methadone, pentamidine</b>
<b>,</b>
<span class="classification">phenothiazines,</span>
<b>probucol, gatifloxacin, gemifloxacin, grepafloxacin, levofloxacin, moxifloxacin, sparfloxacin, tacrolimus</b>
<b>,</b>
<span class="classification">tricyclic antidepressants</span>, <b>amiodarone, clozapine, disopyramide, dofetilide, dolasetron, haloperidol, ibutilide, mesoridazine, palonosetron, pimozide,
         procainamide, quinidine, thioridazine, sotalol, ziprasidone</b> may exacerbate QTc prolongation; may increase CNS depression with other CNS depressants, including <span class="classification">tricyclic antidepressants, anxiolytics, sedatives, hypnotics</span>, <b>dronabinol</b>
<b>,</b>
<span class="classification">general anesthetics</span>, <b>mirtazapine, nefazodone</b>
<b>,</b>
<span class="classification">opiate agonists</span>, <b>pramipexole, ropinirole</b>
<b>,</b>
<span class="classification">skeletal muscle relaxants</span>, <b>tramadol, trazodone</b>.  <span class="typehead">Herbal:</span>
<b>Kava-kava</b> may increase the symptoms of Parkinson's disease. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> SC absorption is dependent on site utilizedabdominal injection absorbed faster than thigh; lowering the temperature
      of the injection site slows absorption. <span class="typehead">Onset:</span> 714 min. <span class="typehead">Peak:</span> 4060 min. <span class="typehead">Duration:</span> Up to 2 h. <span class="typehead">Distribution:</span> 8590% protein bound. <span class="typehead">Metabolism:</span> Metabolized by glucuronidation, sulfation, and N-demethylation. <span class="typehead">Elimination:</span> Excreted by kidneys. <span class="typehead">Half-Life:</span> 3060 min. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">
<b>Assessment &amp; Drug Effects</b>
</span></p>
<ul>
<li>Periodic ECG, especially in those with known CV disease.</li>
<li>Withhold drug &amp; notify physician for S&amp;S of torsades de pointes (i.e., palpitations and syncope), especially in those with
            bradycardia or suspected hypokalemia or hypomagnesemia.
         </li>
<li>Lab tests: Periodic serum electrolytes.</li>
<li>Monitor closely for orthostatic hypotension, especially when doses are increased, and in patients taking antihypertensive
            medications and vasodilators (especially nitrates).
         </li>
</ul>
<p><span class="eductitle">
<b>Patient &amp; Family Education</b>
</span></p>
<ul>
<li>The dosing pen is marked in mL (not mg) increments; a 1 mg dose is equal to 0.1 mL.</li>
<li>Avoid the use of alcohol while taking this drug.</li>
<li>Report promptly any of the following: irregular or fast, pounding heartbeat, or palpitations; dizziness, lightheadedness,
            or fainting; unexplained weakness, tiredness, or sleepiness; confusion, hallucinations, or depression; unusual body movements;
            vomiting; or prolonged painful erections.
         </li>
<li>Do not engage in potentially hazardous activities until reaction to drug is known.</li>
<li>Do not breast feed while taking this drug.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>